Antigenic peptide–major histocompatibility complex class II complex (pMHC-II complex or pMHCII)

Molecular Classification

Other (protein heterodimer complex), Receptor (in the context of being the ligand for T cell receptor), Major histocompatibility complex class II protein

Other Names

peptide–MHC class II complex, pMHCII complex, MHC class II–peptide complex, class II MHC–peptide complex, HLA class II–peptide complex (in humans)

Disease Roles

InfectionAutoimmune disease (e.g., Type 1 diabetes)Cancer (immune surveillance and escape)

Antigenic peptide–major histocompatibility complex class II complex Overview

Antigenic peptide–major histocompatibility complex class II complex refers to a molecular structure formed when a processed peptide (usually 13–25 amino acids in length) binds within the groove of a major histocompatibility complex class II molecule, which itself is typically present on the surface of professional antigen-presenting cells such as dendritic cells, macrophages, and B cells[1][2][4]. The class II molecule is a heterodimer composed of α and β chains, both containing extracellular domains that together create an open-ended peptide-binding groove, distinguishing it from class I MHC proteins[1][4]. These complexes display peptide antigens on the cell surface for recognition by the T cell receptor (TCR) of CD4+ T lymphocytes, which is a fundamental process underlying adaptive immune activation, regulation of immune responses, and maintenance of self-tolerance[2][5][7]. The formation and stability of peptide–MHC II complexes are highly allele-specific and influenced by peptide sequence and affinity, and their presentation is centrally involved in immune surveillance but also contributes to the development of autoimmune and inflammatory diseases[1][6]. They are key therapeutic and diagnostic targets for modulation of immune responses in autoimmunity, infection, transplantation, and cancer immunotherapy[2][5].

Mechanism of Action

Blockade or modulation of antigen presentation to CD4+ T cells Induction or suppression of immune tolerance Alteration of T cell activation thresholds by interfering with the T cell receptor–peptide:MHC II interaction

Biological Functions

Antigen presentation

Immune response

Activation of CD4+ T cells

Initiation of adaptive immunity

Disease Associations

Infection

Autoimmune disease (e.g., Type 1 diabetes)

Cancer (immune surveillance and escape)

Inflammation

Safety Considerations

Off-target immunosuppression (risk of infection, impaired immune surveillance)
Potential for breaking immune tolerance leading to autoimmunity
Cytokine storm or excessive immune activation with superagonists or certain immunotherapies

Interacting Drugs

Abatacept (modulates T cell activation by binding CD80/CD86 and preventing TCR engagement with pMHCII)

Belatacept (similar to abatacept)

Anti-HLA-DR antibodies (for diagnostic or experimental use)

Immunomodulatory agents may modify pMHCII function but no classical "inhibitors" of the complex in clinical use

Associated Biomarkers

Biomarker
HLA-DR or other HLA class II expression (as surrogate of pMHCII abundance)
Presence of specific pMHCII tetramers to identify antigen-specific T cells (research/clinical trials)
MHC II–restricted epitope specificity in T cell profile (research)